Biofil Chemicals Peer Comparison

NSE: BIOFILCHEM | BSE: 524396

₹32.44

₹0.11 (0.34%)

As on 25-Sep-2026IST

Market cap

₹53 Cr

Revenue (TTM)

₹34 Cr

P/E Ratio

110.6

P/B Ratio

Div. Yield

0 %

Edit

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Market cap (₹ Cr)	53	36,827	27,985	27,762	26,788
Revenue (₹ Cr)	34	3,564	9,205	1,936	1,462
Net Profit (₹ Cr)	0.48	414.00	-371.81	288.22	387.35
Net Margin (%)	1.39	11.23	-3.93	14.79	26.01
RoE (%)	2.25	8.38	-3.85	29.77	25.18
Price to Earnings	110.57	90.04	--	96.32	69.36
Price-To-Book	2.98	7.32	3.50	20.68	15.53

Income Statement (₹ Cr)

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Operating Revenue	34.31	3,564.00	9,205.28	1,935.80	1,461.80
Total Income	34.63	3,686.00	9,449.59	1,948.58	1,489.25
Total Expenditure	33.53	2,792.00	8,195.15	1,485.56	919.25
EBITDA	0.78	772.00	1,010.13	450.24	542.56
Depreciation	0.27	226.00	857.51	50.83	37.68
EBIT	0.51	546.00	152.62	399.41	504.88
Interest	0.00	217.00	342.73	40.84	3.77
Other Income	0.31	122.00	244.31	12.78	27.45
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	0.82	463.00	-162.68	371.35	528.56
Provision for Tax	0.34	49.00	209.13	83.14	141.21
Profit after Tax	0.48	414.00	-371.81	288.22	387.35

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Shareholder's Funds	21.56	4,940.00	8,162.62	1,288.82	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.60	1,712.00	5,044.14	202.03	42.40
Current Liabilities	20.69	1,622.00	4,758.28	835.87	230.82
Total Liabilities	42.85	8,578.00	17,723.32	2,326.71	1,983.96

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Non-Current Assets	6.94	5,343.00	10,211.52	519.60	1,026.85
Current Assets	35.86	2,606.00	7,191.66	1,681.81	881.27
Total Assets	42.85	8,578.00	17,723.32	2,326.71	1,983.96
Total Debt*	3.02	2,125.00	5,495.48	259.37	26.49
Net Current Assets	15.17	984.00	2,433.38	845.94	650.46
Contingent Liabilities	--	768.26	95.72	19.09	17.25

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Cash From Operating Activities	-0.60	390.00	1,652.60	205.05	292.17
Cash Flow from Investing Activities	1.14	-241.00	-826.03	-409.72	-265.94
Cash from Financing Activities	2.54	-54.00	-38.98	283.07	4.10
Net Cash Inflow / Outflow	3.07	95.00	787.59	78.39	30.33

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
ROCE (%)	19.06	6.79	1.24	29.22	32.42
ROE (%)	2.25	8.38	-3.85	29.77	25.18
ROA (%)	1.03	4.94	-2.21	24.77	21.93
EBIT Margin (%)	1.49	15.32	1.66	20.63	34.54
Net Margin (%)	1.39	11.23	-3.93	14.79	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Revenue Growth (%)	9.30	18.37	0.78	46.65	40.90
EBIT Growth (%)	156.28	252.26	-70.53	62.13	124.50
Net Profit Growth (%)	-82.79	377.85	-1,383.43	89.49	104.15
EPS Growth (%)	-82.79	1,001.33	-484.84	78.60	42.32
Book Value Growth (%)	18.53	13.47	0.33	144.31	26.03

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Price / Earnings	110.57	92.42	-89.43	94.85	69.36
Price / Book Value	2.98	7.32	3.50	20.68	15.53
Dividend Yield (%)	0.00	0.00	0.00	0.09	0.08
EV/EBITDA	67.59	49.60	31.80	61.47	49.01
Market Cap (₹ Cr)	42.12	19,071.62	18,108.89	12,753.19	20,944.75

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.53	0.11	0.02
Short term debt to equity ratio	0.14	0.09	0.09	0.05	0.02
Current Ratio	1.73	1.61	1.51	2.01	3.82
Quick Ratio	1.54	1.06	0.87	1.14	2.82
Interest Coverage	411.00	3.13	0.53	10.09	141.16

	Biofil Chemicals	Wockhardt	Piramal Pharma	Rubicon Research	Acutaas Chemicals
Debtors to sales (%)	80.40	16.50	23.44	26.28	24.80
Asset Turnover	0.73	0.43	0.55	1.66	0.83
Receivable days	423.56	58.75	78.20	40.13	88.98
Inventory Days	47.18	75.82	93.30	60.29	56.04
Payable days	337.77	186.21	226.14	232.47	99.95
Cash Conversion Cycle	132.97	-51.64	-54.64	-132.04	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.